Status:
TERMINATED
Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)
Lead Sponsor:
Apieron
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE4
Brief Summary
This study is designed to show that pharmacotherapy guided by eNO and clinical standard of care produces a superior outcome to trial-based therapy guided by clinical standard of care alone.
Detailed Description
Patients with persistent, moderate to severe asthma will be randomized to receive therapy guided by either eNO and clinical standard of care (eNO group) or clinical standard of care (control group). A...
Eligibility Criteria
Inclusion
- Pre-existing diagnosis of asthma
- Persistent, moderate or severe asthma as classified by NAEPP
- Sub-optimally controlled asthma
- Initiated ICS therapy for at least the past 30 days and a history of improvement of asthma control on steroids
Exclusion
- Active cigarette smoking or ≥ 10 pack-years smoking history
- Xolair taken in the past 6 months prior to enrollment
- Oral prednisone taken in the last 4 weeks prior to enrollment
- Cystic Fibrosis, COPD, ciliary dyskinesia, chest wall deformities or scoliosis
- Subject is currently enrolled in another investigational drug study
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00739219
Start Date
December 1 2006
End Date
October 1 2008
Last Update
January 21 2009
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern California Research
Mission Viejo, California, United States, 92691
2
Allergy & Asthma Associates of Santa Clara Valley Research Center
San Jose, California, United States, 95117
3
Allergy Associates of Hartford
Glastonbury, Connecticut, United States, 06033
4
Asthma and Allergy Center of Chicago, S.C.
River Forest, Illinois, United States, 60305